Onco Therapeutics
Publicou 4 edições por ano
ISSN Imprimir: 2694-4642
ISSN On-line: 2694-4650
Indexed in
Immune Complex Analysis in Active Lyme Disease
Volume 7,
Edição 3-4, 2016,
pp. 213-224
DOI: 10.1615/ForumImmunDisTher.2017019621
RESUMO
Lyme disease (LD) is a growing infectious disease. Assays that can detect active infection early are needed to allow appropriate antibiotic therapy to begin when there is the best chance for a cure. The most frequently used assays are those based on antibodies to Borrelia burgdorferi or its variants, the causative agent of LD. However, an antibody test at a single time point only measures exposure, not necessarily an active infection. In contrast, antibodies that are bound to a target antigen in a circulating immune complex form do indicate active infection. Here, we present data supporting the use of such assays in LD.
618 Visualizações do artigo
11 downloads de artigos
Métricas
Artigos com conteúdo semelhante:
Última edição
Preface: Phytochemicals for Colorectal Cancer Therapy
Novel and Latest Computational and Development of Anticancer Cancer
Isoquinoline Alkaloids: Promising Natural Compounds for Targeting Angiogenesis and Metastasis in Colon Cancer
Naringenin in the Prevention of Colon Cancer: An Updated Review
Anti-Cancer Pectins and Their Role in Colorectal Cancer Treatment
Citrus Flavones Luteolin and Apigenin Target Fundamental Mechanisms in Colon Cancer
Dietary Phytocompounds for Colon Cancer Therapy
Nano-Formulation for Curcumin and Resveratrol in Colorectal Cancer Therapy